4 free views remaining today

congenital disorder of glycosylation If

Description

Congenital Disorders of Glycosylation (CDG): A Rare Genetic Condition

Congenital disorders of glycosylation (CDG) is a group of rare genetic disorders that affect how sugars attach to proteins and fats in the body [4]. This condition is caused by defects in various steps along glycan biosynthesis, leading to impaired protein function and cellular dysfunction [2].

Symptoms and Characteristics

Individuals with CDG may experience a range of symptoms, including:

  • Developmental delays
  • Imbalance
  • Muscle weakness
  • Nerve damage
  • Vision issues
  • Gastrointestinal problems
  • Poor growth
  • Liver disease [3]

Some individuals with CDG may also have distinctive facial features, such as a high forehead, triangular face, large ears, and thin upper lip [5].

Types of CDG

CDG is a genetically and clinically heterogeneous group of diseases, with over 130 distinct conditions identified [1]. These conditions can be caused by defects in various steps along glycan biosynthesis, including the synthesis of oligosaccharides [6].

References:

[1] IJ Chang · 2018 · Cited by 247 — Congenital disorders of glycosylation are a genetically and clinically heterogeneous group of >130 diseases caused by defects in various steps along glycan ...

[2] by DM Krasnewich · Cited by 2 — Congenital disorders of glycosylation (CDGs) are a group of over 100 monogenic human diseases with defects in the synthesis of oligosaccharides ...

[3] Jun 12, 2024 — Developmental delays. · Imbalance. · Muscle weakness. · Nerve damage. · Vision issues. · Gastrointestinal problems. · Poor growth. · Liver disease.

[4] Congenital disorders of glycosylation (CDG) is a group of rare genetic disorders that affect how sugars attach to proteins and fats in the body.

[5] Distinctive facial features are sometimes present in affected individuals, including a high forehead, a triangular face , large ears, and a thin upper lip .

[6] by IJ Chang · 2018 · Cited by 247 — Congenital disorders of glycosylation are a genetically and clinically heterogeneous group of >130 diseases caused by defects in various steps along glycan ...

Additional Characteristics

  • Gastrointestinal problems
  • Imbalance
  • Muscle weakness
  • Nerve damage
  • Developmental delays
  • Liver disease
  • Poor growth
  • Congenital disorders of glycosylation (CDG)
  • Vision issues
  • Distinctive facial features (high forehead, triangular face, large ears, thin upper lip)
  • >130 distinct conditions identified

Signs and Symptoms

Common Signs and Symptoms of Congenital Disorder of Glycosylation (CDG)

CDG, also known as Congenital Disorder of Glycosylation, is a rare genetic disorder that affects the body's ability to properly attach sugar molecules to proteins. This can lead to a wide range of symptoms, which can vary in severity from mild to severe.

Common Symptoms:

  • Developmental delays [2]
  • Muscle weakness
  • Nerve damage
  • Imbalance
  • Poor growth

Additional Symptoms:

  • Floppy muscle tone (hypotonia) [3]
  • Abnormal bleeding or blood clotting
  • Crossed or misaligned eyes (strabismus)
  • Distinctive facial features, such as a high forehead, triangular face, large ears, and thin upper lip [4]

Type-Specific Symptoms:

  • PGM1-CDG: muscle weakness, short stature, cleft palate, blood clotting problems, and liver disease [5]
  • PMM2-CDG: stable cognitive delay, peripheral neuropathy, and progressive thoracic and spinal issues in adults [6]
  • SRD5A3-CDG: intellectual disability, vision problems, unusual facial features, low muscle tone (hypotonia), and crossed eyes (strabismus) [7]

Other Symptoms:

  • Abnormal fat distribution
  • Bleeding or blood clotting issues
  • Vomiting and diarrhea
  • Distinctive facial features

It's essential to note that the severity and range of symptoms can vary significantly among individuals with CDG. If you suspect someone may have this condition, it's crucial to consult a medical professional for proper diagnosis and treatment.

References: [1] - Not applicable (CDG context) [2] - Jun 12, 2024 [3] - What are the symptoms of CDG? [4] - Distinctive facial features are sometimes present in affected individuals... [5] - PGM1-CDG – Symptoms may include muscle weakness, short stature... [6] - by IJ Chang · 2018 · Cited by 247 — Adults with PMM2-CDG may live until their 7th or 8th decades... [7] - Sep 27, 2021 — Most individuals with SRD5A3-CDG have intellectual disability...

Additional Symptoms

  • Imbalance
  • Nerve damage
  • Distinctive facial features
  • Developmental delays
  • Abnormal fat distribution
  • Bleeding or blood clotting issues
  • Vomiting and diarrhea
  • Poor growth
  • Abnormal bleeding or blood clotting
  • Crossed or misaligned eyes (strabismus)
  • Floppy muscle tone (hypotonia)
  • muscle weakness

Diagnostic Tests

Diagnostic Tests for Congenital Disorder of Glycosylation (CDG)

Congenital disorders of glycosylation (CDG) are a group of rare genetic disorders that affect the body's ability to properly attach sugars to proteins and lipids. Diagnostic tests play a crucial role in identifying CDG, which can help guide treatment and management decisions.

Recommended First-Tier Test

The recommended first-tier test for screening patients with suspected congenital disorders of glycosylation (CDG) is a biochemical test that analyzes transferrin and apolipoprotein C-III [3]. This test is useful for identifying defects in N-linked protein glycosylation, which is a common feature of CDG.

Other Diagnostic Tests

In addition to the first-tier test, other diagnostic tests may be used to confirm or rule out CDG. These include:

  • Serum Transferrin Isoelectrofocusing: This test is often considered the standard first screen test for N-linked protein glycosylation disorders [4].
  • ESI-TOF/MS (Electrospray Ionization-Time of Flight/Mass Spectrometry): This high-resolution mass spectrometry technique can precisely identify diagnostic N-glycans and is useful for confirming CDG due to N-glycosylation defects [6].
  • Blood Test: A simple blood test analyzing the glycosylation status of transferrin can help diagnose or confirm many cases of CDG due to N-glycosylation defects [7].

Genetic Testing

In some cases, genetic testing may be used to confirm a diagnosis of CDG. This can include:

  • 48-Gene Panel: A 48-gene panel that includes assessment of non-coding variants is ideal for patients with a clinical suspicion of a congenital disorder of glycosylation [8].
  • Clinical Genetic Test: A clinical genetic test offered by PreventionGenetics, part of Exact Sciences, can be used to diagnose conditions associated with CDG, such as ALG1-congenital disorder of glycosylation and ALG11-congenital disorder of glycosylation [9].

It's essential to note that the choice of diagnostic tests may vary depending on individual patient circumstances and clinical presentation. A comprehensive evaluation by a qualified healthcare professional is necessary for accurate diagnosis and management of CDG.

References:

[1] Marklová, E. (2007). Diagnostics of congenital disorders of glycosylation: A review. [Context 1]

[2] [Context 2]

[3] [Context 3]

[4] [Context 4]

[5] [Context 5]

[6] [Context 6]

[7] [Context 7]

[8] [Context 8]

[9] [Context 9]

Additional Diagnostic Tests

  • Blood Test
  • Clinical Genetic Test
  • Serum Transferrin Isoelectrofocusing
  • Mass Spectrometry)
  • 48-Gene Panel

Treatment

Treatment Options for Congenital Disorders of Glycosylation (CDG)

According to various studies and medical reviews, the treatment of CDG is primarily focused on managing symptoms rather than addressing the underlying cause. However, some promising therapeutic approaches have been explored in recent years.

  • Nutritional Therapies: Oral galactose supplementation has shown improved seizure control in patients with certain forms of CDG (Verheijen et al., 2020 [4]). Additionally, oral manganese therapy has also demonstrated benefits in managing seizures (Verheijen et al., 2020 [4]).
  • Oral Mannose Supplementation: This therapy has been successfully used to restore glycosylation in patients with PMM2-CDG (Monticelli et al., 2023 [7]). Oral mannose supplementation may also be beneficial for other forms of CDG.
  • Epalrestat: A drug initially developed for diabetic neuropathy, epalrestat has shown promise in treating PMM2-CDG. Clinical trials are planned to further investigate its efficacy (Park et al., 2021 [2]).
  • Gene Therapy: While still in the experimental stages, gene therapy holds potential for addressing the underlying cause of CDG.
  • Activated Sugars and Transplantation: These therapies have been explored as potential treatments for certain forms of CDG.

It is essential to note that each patient's response to these treatment options may vary, and a comprehensive treatment plan should be tailored to individual needs. Consultation with a medical professional is crucial for determining the most effective course of action.

References: [1] Verheijen et al., 2020 [4] [2] Park et al., 2021 [2] [3] Monticelli et al., 2023 [7] [4] Verheijen et al., 2020 [4] [5] Brasil et al., 2022 [9]

Please let me know if you would like me to expand on any of these points or provide further information.

Recommended Medications

  • Gene Therapy
  • Oral Mannose Supplementation
  • Epalrestat
  • Manganese Therapy
  • Activated Sugars and Transplantation
  • galactose
  • Galactose

💊 Drug information is sourced from ChEBI (Chemical Entities of Biological Interest) database. Always consult with a healthcare professional before starting any medication. Click on any medication name for detailed information.

Differential Diagnosis

Differential Diagnosis of Congenital Disorder of Glycosylation Type I (CDG-I)

Congenital disorders of glycosylation, including CDG-I, often present as multisystem disorders. As a result, affected individuals may be incorrectly diagnosed with other disorders. According to the CDG Hub, differential diagnosis is crucial in identifying CDG-I.

  • Other Disorders that May Be Misdiagnosed: CDG-I may be mistaken for other conditions such as:
    • Non-immune hydros fetalis
    • Cerebellar hypoplasia
    • Skeletal deformities
    • Polyhydramnios
    • Ballantyne syndrome [6]
  • Importance of Accurate Diagnosis: Misdiagnosis can lead to inappropriate treatment and delayed diagnosis. Therefore, it is essential to consider CDG-I in the differential diagnosis of patients presenting with symptoms suggestive of this condition.
  • Genetic Heterogeneity: Congenital disorders of glycosylation are a genetically heterogeneous group of autosomal recessive disorders caused by enzymatic defects in the synthesis of glycans [10]. This genetic heterogeneity can make differential diagnosis more challenging.

Accurate diagnosis and differentiation from other conditions require a comprehensive evaluation, including clinical presentation, laboratory tests, and genetic analysis. A multidisciplinary approach involving specialists such as pediatricians, geneticists, and biochemists is often necessary to confirm the diagnosis of CDG-I.

References: [6] CDG Hub — Differential Diagnosis. [10] Congenital disorders of glycosylation (CDGs) are a genetically heterogeneous group of autosomal recessive disorders caused by enzymatic defects in the synthesis ...

Additional Differential Diagnoses

Additional Information

rdf-schema#domain
https://w3id.org/def/predibionto#has_symptom_3429
owl#annotatedSource
t353891
oboInOwl#hasOBONamespace
disease_ontology
oboInOwl#id
DOID:0080558
core#notation
DOID:0080558
oboInOwl#hasDbXref
ORDO:79323
oboInOwl#hasExactSynonym
congenital disorder of glycosylation 1f
rdf-schema#label
congenital disorder of glycosylation If
IAO_0000115
A congenital disorder of glycosylation I that is characterized by psychomotor delay, seizures, failure to thrive, and cutaneous and ocular anomalies and has_material_basis_in homozygous or compound heterozygous mutation in the MPDU1 gene on chromosome 17p13.
rdf-schema#subClassOf
t353876
oboInOwl#inSubset
http://purl.obolibrary.org/obo/doid#DO_rare_slim
IDO_0000664
http://purl.obolibrary.org/obo/GENO_0000148
RO_0004019
http://purl.obolibrary.org/obo/HP_0001197
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class

Medical Disclaimer: The information provided on this website is for general informational and educational purposes only.

It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with questions about your medical condition.